Search

Your search keyword '"Brenneman, Randall J."' showing total 32 results
Start Over Author "Brenneman, Randall J."
32 results on '"Brenneman, Randall J."'

7. Does the sequence of high-dose rate brachytherapy boost and IMRT for prostate cancer impact early toxicity outcomes? Results from a single institution analysis

Author

Roy, Amit, Brenneman, Randall J., Hogan, Jacob, Barnes, Justin M., Huang, Yi, Morris, Robert, Goddu, Sreekrishna, Altman, Michael, Garcia-Ramirez, Jose, Li, Harold, Zoberi, Jacqueline E., Bullock, Arnold, Kim, Eric, Smith, Zachary, Figenshau, Robert, Andriole, Gerald L., Baumann, Brian C., Michalski, Jeff M., and Gay, Hiram A.

Published
2021
Full Text
View/download PDF

10. Overall survival comparison between androgen deprivation therapy (ADT) plus external beam radiation therapy (EBRT) vs ADT plus EBRT with brachytherapy boost in clinically node-positive prostate cancer

Author

Fischer-Valuck, Benjamin W., Rao, Yuan James, Brenneman, Randall J., Patel, Pretesh R., Filson, Christopher P., Jani, Ashesh B., Liu, Yuan, Goyal, Subir, Xu, Karen, Weiss, Aaron, Kucuk, Omer, Cimmino, Cara, Szabo, Stephen, Rossi, Peter, Baumann, Brian C., Pattaras, John, Hershatter, Bruce, and Patel, Sagar A.

Published
2020
Full Text
View/download PDF

11. A Pilot Study of Simulation-Free Hippocampal-Avoidance Whole Brain Radiotherapy Using Diagnostic MRI-Based and Online Adaptive Planning

Author

Kang, Kylie H., primary, Price, Alex T., additional, Reynoso, Francisco J., additional, Laugeman, Eric, additional, Morris, Eric D., additional, Samson, Pamela P., additional, Huang, Jiayi, additional, Badiyan, Shahed N., additional, Kim, Hyun, additional, Brenneman, Randall J., additional, Abraham, Christopher D., additional, Knutson, Nels C., additional, and Henke, Lauren E., additional

Published
2024
Full Text
View/download PDF

12. Association Between Local Radiation Therapy to the Primary Bladder Tumor and Overall Survival for Patients with Metastatic Urothelial Cancer Receiving Systemic Chemotherapy

Author

Fischer-Valuck, Benjamin W., Patel, Sagar A., Brenneman, Randall J., Christodouleas, John, Sargos, Paul, Kim, Eric, Weiss, Aaron, Hershatter, Bruce, Rao, Yuan J., Picus, Joel, Roth, Bruce, Arora, Vivek, Carmona, Ruben, Reimers, Melissa, Zaghloul, Mohamed S., Gay, Hiram, Michalski, Jeff M., and Baumann, Brian C.

Subjects
Male, Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Oncology, Urology, Urinary Bladder, Humans, Female, Radiology, Nuclear Medicine and imaging, Surgery, Prospective Studies, Article, Retrospective Studies
Abstract

There are limited data on the role of local therapy for metastatic urothelial carcinoma of the bladder (mUC). In this retrospective cohort analysis, we queried the National Cancer Data Base for patients with newly diagnosed mUC (cT1-4 N0-3 M1). Overall survival (OS) was compared between treatment with chemotherapy (CT) alone (n = 4122) and CT plus bladder-directed radiation therapy (CT + RT; n = 337). Multivariable Cox proportional-hazards analyses and matching and landmark analyses were performed. CT + RT was independently associated with better OS (hazard ratio 0.70, 95% confidence interval 0.62-0.79; p0.0001) and this result persisted in matched and landmark analyses. These findings are hypothesis-generating and limited by inherent confounding factors; however, a prospective trial evaluating the impact of bladder RT in mUC is warranted. PATIENT SUMMARY: For patients with bladder cancer that has already spread to other parts of the body, it is unclear if radiation therapy directed at the primary bladder tumor would provide any improvement in survival. In this study, we found that aggressive radiation therapy directed at the bladder combined with chemotherapy may provide a survival benefit in some patients with metastatic bladder cancer compared to chemotherapy alone.

Published
2022
Full Text
View/download PDF

14. Survival Outcomes in Men with Unfavorable Intermediate-Risk and High-Risk Prostate Cancer Treated with Prostate-Only versus Whole Pelvic Radiation Therapy

Author

Andruska, Neal, primary, Fischer-Valuck, Benjamin W., additional, Waters, Michael, additional, Juarez Diaz, Elizabeth, additional, Agabalogun, Temitope, additional, Kim, Eric H., additional, Smith, Zachary L., additional, Brenneman, Randall J., additional, Gay, Hiram A., additional, Andriole, Gerald L., additional, Michalski, Jeff M., additional, and Baumann, Brian C., additional

Published
2022
Full Text
View/download PDF

15. Reply by Authors

Author

Andruska, Neal, primary, Fischer-Valuck, Benjamin W., additional, Waters, Michael, additional, Juarez Diaz, Elizabeth, additional, Agabalogun, Temitope, additional, Kim, Eric H., additional, Smith, Zachary L., additional, Brenneman, Randall J., additional, Gay, Hiram A., additional, Andriole, Gerald L., additional, Michalski, Jeff M., additional, and Baumann, Brian C., additional

Published
2022
Full Text
View/download PDF

16. Outcomes of Unfavorable Intermediate-Risk Prostate Cancer Patients Treated with External Beam Radiotherapy vs. Brachytherapy Alone

Author

Andruska, Neal, Fischer-Valuck, Benjamin W., Carmona, Ruben, Agabalogun, Temitope, Brenneman, Randall J., Gay, Hiram A., Michalski, Jeff M., and Baumann, Brian C.

Subjects
Article
Abstract

The NCCN Guidelines for Prostate Cancer currently recommend several definitive radiotherapy (RT) options for men with unfavorable intermediate-risk (UIR) prostate cancer: external-beam RT (EBRT) plus androgen deprivation therapy (ADT) or EBRT plus brachytherapy boost with or without ADT. However, brachytherapy alone with or without ADT is not well defined and is currently not recommended for UIR prostate cancer. We hypothesized that men treated with brachytherapy with or without ADT have comparable survival rates to men treated with EBRT with or without ADT.A total of 31,783 men diagnosed between 2004 and 2015 with UIR prostate cancer were retrospectively reviewed from the National Cancer Database. Men were stratified into 4 groups: EBRT (n=12,985), EBRT plus ADT (n=12,960), brachytherapy (n=4,535), or brachytherapy plus ADT (n=1,303). Inverse probability of treatment weighting (IPTW) was used to adjust for covariable imbalances, and weight-adjusted multivariable analysis (MVA) using Cox regression modeling was used to compare overall survival (OS) hazard ratios (HRs).Relative to EBRT alone, the following treatments were associated with improved OS: EBRT plus ADT (HR, 0.92; 95% CI, 0.87-0.97; P=.002), brachytherapy alone (HR, 0.90; 95% CI, 0.83-0.98; P=.01), and brachytherapy plus ADT (HR, 0.78; 95% CI, 0.69-0.88; P=.00006). Brachytherapy correlated with improved OS relative to EBRT in men who were not treated with ADT (HR, 0.92; 95% CI, 0.84-0.99; P=.03) and in those receiving ADT (HR, 0.84; 95% CI, 0.75-0.95; P=.004). At 10-year follow-up, 56% and 63% of men receiving EBRT and brachytherapy, respectively, were alive (P.0001). IPTW was used to determine the average treatment effect of definitive brachytherapy. Relative to EBRT, definitive brachytherapy correlated with improved OS (HR, 0.90; 95% CI, 0.84-0.97; P=.009) on weight-adjusted MVA.Definitive brachytherapy was associated with improved OS compared with EBRT. The addition of ADT to both EBRT and definitive brachytherapy was associated with improved OS. These results suggest that definitive brachytherapy should be considered as an option for men with UIR prostate cancer.

Published
2022

18. Is the addition of brachytherapy and/or androgen deprivation therapy associated with improved overall survival in unfavorable intermediate-risk prostate cancer patients treated with external beam radiotherapy?

Author

Andruska, Neal, Fischer-Valuck, Benjamin W., Carmona, Ruben, Agabalogun, Temitope, Brenneman, Randall J., Gay, Hiram A., Michalski, Jeff M., and Baumann, Brian C.

Subjects
Male, Brachytherapy, Androgens, Humans, Prostatic Neoplasms, Androgen Antagonists, Article, Retrospective Studies
Abstract

BACKGROUND: Current recommendations regarding radiotherapy treatment for unfavorable intermediate-risk prostate cancer (UIR-PCa) include external beam radiotherapy (EBRT) ± brachytherapy boost (BT) ± androgen deprivation therapy (ADT). The ideal radiotherapy treatment approach for UIR-PCa has not been well-defined. We hypothesized that EBRT+BT±ADT is associated with improved overall survival (OS) relative to EBRT±ADT in men with UIR-PCa. MATERIALS AND METHODS: The National Cancer Database (NCDB) was used to retrospectively identify 32,246 men diagnosed between 2004–2015 with UIR-PCa who received EBRT (n=13,265), EBRT+ADT (n=13,123), EBRT+BT (n=3,440), or EBRT+BT+ADT (n=2,418). OS was the primary outcome. Inverse probability of treatment weighting was used to adjust for covariable imbalances and weight-adjusted multivariable analysis (MVA) using Cox regression modeling was used to compare OS hazard ratios. RESULTS: Median follow-up was 60 months (range: 3–168 months). EBRT+ADT correlated with improved OS relative to EBRT alone on MVA (Hazard Ratio (HR): 0.92, [95% Confidence Interval: 0.87–0.98], p=.005). Compared to EBRT+ADT, EBRT+BT (HR: 0.77 [0.69–0.85], p=3×10(−7)) and EBRT+BT+ADT (HR: 0.75 [0.67–0.83], p=6×10(−8)) were associated with improved OS. 8-year OS for the EBRT+ADT versus EBRT+BT+ADT was 70% and 78% (p

Published
2022

21. PRSOR07 Presentation Time: 12:30 PM

Author

Roy, Amit, primary, Brenneman, Randall J., additional, Hogan, Jake, additional, Barnes, Justin, additional, Huang, Yi, additional, Morris, Robert, additional, Goddu, S. Murty, additional, Michael, Altman, additional, Garcia-Ramirez, Jose, additional, Li, Harold, additional, Zoberi, Jacqueline E., additional, Bullock, Arnold, additional, Kim, Eric, additional, Smith, Zachary, additional, Figenshau, Robert, additional, Andriole, Gerald, additional, Baumann, Brian, additional, Michalski, Jeff, additional, and Gay, Hiram, additional

Published
2021
Full Text
View/download PDF

23. PRSOR01 Presentation Time: 12:00 PM

Author

Andruska, Neal D., primary, Michalski, Jeff M., additional, Agabalogun, Temitope, additional, Brenneman, Randall J., additional, Gay, Hiram A., additional, Fischer-Valuck, Benjamin W., additional, and Baumann, Brian C., additional

Published
2021
Full Text
View/download PDF

25. Review: Brain Metastases in Bladder Cancer

Author

Brenneman, Randall J., primary, Gay, Hiram A., additional, Christodouleas, John P., additional, Sargos, Paul, additional, Arora, Vivek, additional, Fischer-Valuck, Benjamin, additional, Huang, Jiayi, additional, Knoche, Eric, additional, Pachynski, Russell, additional, Picus, Joel, additional, Reimers, Melissa, additional, Roth, Bruce, additional, Michalski, Jeff M., additional, and Baumann, Brian C., additional

Published
2020
Full Text
View/download PDF

29. Central regulation of photosensitive membrane turnover in the lateral eye ofLimulus. II. Octopamine actsviaadenylate cyclase/cAMP-dependent protein kinase to prime the retina for transient rhabdom shedding

Author

RUNYON, SCOTT L., primary, WASHICOSKY, KEVIN J., additional, BRENNEMAN*, RANDALL J., additional, KELLY, JEREMY R., additional, KHADILKAR, RASHMI V., additional, HEACOCK, KEVIN F., additional, MCCORMICK, SHAELAN M., additional, WILLIAMS, KELLY E., additional, and JINKS, ROBERT N., additional

Published
2004
Full Text
View/download PDF

31. A Pilot Study of Simulation-Free Hippocampal-Avoidance Whole Brain Radiation Therapy Using Diagnostic MRI-Based and Online Adaptive Planning.

Author

Kang, Kylie H., Price, Alex T., Reynoso, Francisco J., Laugeman, Eric, Morris, Eric D., Samson, Pamela P., Huang, Jiayi, Badiyan, Shahed N., Kim, Hyun, Brenneman, Randall J., Abraham, Christopher D., Knutson, Nels C., and Henke, Lauren E.

Subjects
*MAGNETIC resonance imaging, *RADIOTHERAPY, *VOLUMETRIC-modulated arc therapy, *CONE beam computed tomography, *COMPUTED tomography, *PILOT projects
Abstract

We aimed to demonstrate the clinical feasibility and safety of simulation-free hippocampal avoidance whole brain radiation therapy (HA-WBRT) in a pilot study (National Clinical Trial 05096286). Ten HA-WBRT candidates were enrolled for treatment on a commercially available computed tomography (CT)-guided linear accelerator with online adaptive capabilities. Planning structures were contoured on patient-specific diagnostic magnetic resonance imaging (MRI), which were registered to a CT of similar head shape, obtained from an atlas-based database (AB-CT). These patient-specific diagnostic MRI and AB-CT data sets were used for preplan calculation, using NRG-CC001 constraints. At first fraction, AB-CTs were used as primary data sets and deformed to patient-specific cone beam CTs (CBCT) to give patient-matched density information. Brain, ventricle, and brain stem contours were matched through rigid translation and rotation to the corresponding anatomy on CBCT. Lens, optic nerve, and brain contours were manually edited based on CBCT visualization. Preplans were then reoptimized through online adaptation to create final, simulation-free plans, which were used if they met all objectives. Workflow tasks were timed. In addition, patients underwent CT-simulation to create immobilization devices and for prospective dosimetric comparison of simulation-free and simulation-based plans. Median time from MRI importation to completion of "preplan" was 1 weekday (range, 1-4). Median on-table workflow duration was 41 minutes (range, 34-70). NRG-CC001 constraints were achieved by 90% of the simulation-free plans. One patient's simulation-free plan failed a planning target volume coverage objective (89% instead of 90% coverage); this was deemed acceptable for first-fraction delivery, with an offline replan used for subsequent fractions. Both simulation-free and simulation CT-based plans otherwise met constraints, without clinically meaningful differences. Simulation-free HA-WBRT using online adaptive radiation therapy is feasible, safe, and results in dosimetrically comparable treatment plans to simulation CT-based workflows while providing convenience and time savings for patients. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

32. Propensity-Weighted Survival Analysis of SBRT vs. Conventional Radiotherapy in Unfavorable Intermediate-Risk Prostate Cancer

Author

Andruska, Neal, Fischer-Valuck, Benjamin W., Agabalogun, Temitope, Carmona, Ruben, Brenneman, Randall J., Huang, Yi, Gay, Hiram A., Michalski, Jeff M., and Baumann, Brian C.

Abstract

Prostate stereotactic body radiotherapy (SBRT), which delivers high-dose precision treatment in ≤5 fractions, is a shorter, more convenient, and less expensive alternative to conventionally fractionated radiotherapy (CRFT; ∼44 fractions) or moderately hypofractionated radiotherapy (MFRT; 20-28 fractions). SBRT has not been widely adopted but may have radiobiologic advantages over CFRT/MFRT. We hypothesized that SBRT would be associated with improved overall survival (OS) versus CFRT or MFRT ± androgen deprivation therapy (ADT) for unfavorable-intermediate-risk prostate cancer (UIR-PCa).

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results